Business, energy, technology, markets and global industry news from Business News Today

AIDS 2026

PharmaDeviceNews AIDS 2026
A healthcare professional discusses HIV testing and treatment access as AIDS Healthcare Foundation and the Pan American Health Organization collaborate to tackle late diagnosis across Latin America and the Caribbean. Representative image.
Medical Devices & Diagnostics

Why the new AHF and PAHO HIV partnership faces a harder challenge than expanding testing

AHF and PAHO will expand early HIV testing and linkage to care as late diagnosis continues to drive preventable deaths across the region.

Read More
ViiV Healthcare’s two-drug Dovato regimen matched the three-drug Biktarvy regimen for viral suppression at Week 48 in the head-to-head VOGUE HIV study. Representative image.
Pharma & Biotech

ViiV Healthcare challenges three-drug HIV standard with positive Dovato VOGUE data

ViiV Healthcare’s VOGUE trial found Dovato non-inferior to Biktarvy at Week 48, sharpening the debate over two-drug first-line HIV care.

Read More
Merck is preparing a global access network for alimatravir as the investigational once-monthly oral HIV PrEP candidate advances through Phase 3 trials, with efficacy, affordability and manufacturing readiness set to determine its future public health impact. Representative image.
Pharma & Biotech

Merck is licensing alimatravir before Phase 3 ends. Can a monthly HIV pill beat the access clock?

Merck’s alimatravir access plan covers 129 countries, but Phase 3 efficacy, pricing and regulatory execution will decide its HIV PrEP impact.

Read More
Gilead Sciences and Merck’s investigational once-weekly HIV pill maintained virological suppression in the Phase 3 ISLEND-1 and ISLEND-2 trials. Representative image.
Pharma & Biotech

Can one HIV pill a week replace daily therapy? Gilead and Merck’s Phase 3 data raise the stakes

Gilead and Merck’s weekly HIV pill preserved suppression in two Phase 3 trials, strengthening the case for regulatory filings.

Read More